{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-038617","form_type":"8-K","ticker":"PRME","cik":"0001894562","company_name":"Prime Medicine, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.537274+00:00","generated_at":"2026-05-17T18:25:17.046346+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Prime Medicine Q2: positive CGD clinical data, $144M offering, cash runway into 2027","bullets":["First clinical proof-of-concept for Prime Editing: two patients in CGD trial showed restored NADPH oxidase activity above clinical benefit threshold.","Completed $144.2M follow-on offering in August 2025; cash balance pro-forma $259.6M as of June 30, 2025.","Secured up to $24M from Cystic Fibrosis Foundation to advance CF program targeting G542X mutation.","Allan Reine named CEO in May 2025; strategic restructuring and workforce reduction expected to cut cash needs by half through 2027.","Net loss of $52.6M in Q2 2025 (vs. $55.3M in Q2 2024); R&D expenses down to $41.4M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-038617","json":"https://secwatch.observer/filing/0001628280-25-038617.json","markdown":"https://secwatch.observer/filing/0001628280-25-038617.md","text":"https://secwatch.observer/filing/0001628280-25-038617.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1894562/000162828025038617/0001628280-25-038617-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1894562/000162828025038617/prme-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T18:25:17.046346+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}